Early- and late-onset Alzheimer disease: Are they the same entity?
نویسندگان
چکیده
منابع مشابه
SORL1 mutations in early- and late-onset Alzheimer disease
OBJECTIVE To characterize the clinical and molecular effect of mutations in the sortilin-related receptor (SORL1) gene. METHODS We performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants. The phenotypic consequences associated with SORL1 mutations were characterized based on cli...
متن کاملPathophysiology of Late Onset Alzheimer Disease
As the world population has aged, the number of people affected by Alzheimer Disease is rapidly increasing in the world. It is important for clinicians to recognize early signs and symptoms of dementia and to note potentially modifiable risk factors and early disease markers. Accumulation of A┚ peptides may be the key event in pathogenesis of AD. The exact mechanism by which A┚ peptide depositi...
متن کامل99mTc-TRODAT-1 SPECT Imaging in Early and Late Onset Parkinson’s Disease
Objective(s): 99mTc-TRODAT-1, which binds to the dopamine transporter, could be used to image the dopaminergic system in diagnosis of Parkinson’s disease (PD). PD can be classified into two groups: late onset Parkinson’s disease (LOPD) and early onset Parkinson’s disease (EOPD). In this study we tried to determine the TRODAT SPECT findings in EOPD as compared to LOPD.Methods: Fifteen patients w...
متن کاملEarly-onset versus typical childhood absence epilepsy: Are they all the same thing?
Sir, We read with interest the article by Asadi-Pooya et al. who reported a cross-sectional retrospective study comparing the demographic and electroclinical data of 30 patients with newly diagnosed typical childhood absence epilepsy (CAE) and 16 with newly diagnosed early-onset CAE (i.e., absence seizures starting before 4 years of age). The differences between the two groups with regard to se...
متن کاملGenetic testing for early-onset Alzheimer disease.
The availability of testing for identified risk genes for Alzheimer disease (AD) in patients with clinically probable AD or their at-risk family members raises important questions for the neurologist. Because the potential benefits and risks of testing vary for each patient, physicians need to evaluate whether it is appropriate on a case-by-case basis. This article outlines the testing decision...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurología (English Edition)
سال: 2018
ISSN: 2173-5808
DOI: 10.1016/j.nrleng.2015.08.009